Results 151 to 160 of about 5,369,336 (287)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Parotid Metastases from Head-Neck Cutaneous Squamous Cell Carcinoma: A Prognostic Stratification. [PDF]

Curr Oncol
Togo G, Calabrese L, Orabona GD, Ionna F, Longo F, de Falco R, Perotti P, Piccin O, Gazzini L.   +8 more
europepmc   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK/ERK Signalling. [PDF]

Exp Dermatol
Xue S, Shen Y, Zhang C, Ye Q, Zhang Y, Xu H, He Y.   +6 more
europepmc   +1 more source

Arrhythmias associated with immune checkpoint inhibitor therapy—A clinical perspective

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but are associated with a growing spectrum of cardiovascular immune‐related adverse events. Among these, arrhythmias represent a rare yet potentially life‐threatening complication. ICI‐induced arrhythmias encompass a wide clinical spectrum, including atrial arrhythmias, conduction ...
Dong Wang, Melanie Ricke‐Hoch, David Duncker, Johann Bauersachs, Dominik Berliner   +4 more
wiley   +1 more source

Treating cutaneous squamous cell carcinoma using 5-aminolevulinic acid polylactic-co-glycolic acid nanoparticle-mediated photodynamic therapy in a mouse model

, 2015
Xiaojie Wang,1,2,* Lei Shi,2,* Qingfeng Tu,2 Hongwei Wang,3 Haiyan Zhang,2 Peiru Wang,2 Linglin Zhang,2 Zheng Huang,4 Feng Zhao,5 Hansen Luan,5 Xiuli Wang2 1Shanghai Skin Diseases Clinical College of Anhui Medical University, 2Shanghai Skin Disease ...
Luan H, Shi L, Wang P, Tu Q, Huang Z, Zhang H, Zhao F, Wang X, Wang H, Zhang L   +9 more
core  

Immunotherapy for early-stage cutaneous squamous cell carcinoma. [PDF]

J Immunother Cancer
Boutros A, Kuo YJ, Menzies AM, Long GV, Spagnolo F, Pires da Silva I.   +5 more
europepmc   +1 more source

Extracellular vesicles in pharmacology: Innovations in drug delivery and therapeutic applications in cancer

British Journal of Pharmacology, EarlyView.
Extracellular vesicles (EVs) are a diverse population of membrane nanoparticles secreted by nearly all cell types, playing a key role in intercellular communication by transferring bioactive macromolecular cargo. In cancer, EVs shape both the local tumour microenvironment and distant premetastatic niches.
Evangelia Pantazaka, Georgios Sivvas, Evangelia Papadimitriou, Constantinos M. Mikelis   +3 more
wiley   +1 more source

Inhibitory effects of cold atmospheric plasma-activated solution on cutaneous squamous cell carcinoma. [PDF]

Front Pharmacol
Wang J, Zhang Z, Cheng B, Zhao X, Yin T, Ni T, Du W, Liu X, Feng S, He K, Zhang J, Sun Y, Xu D, Zheng Y.   +13 more
europepmc   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source